- Dosing is underway in a Phase 1 clinical trial assessing the safety and activity of Seattle Genetics' (NASDAQ:SGEN) SGN-CD48A in 75 patients with relapsed/refractory multiple myeloma (MM). Patients will receive an intravenous infusion every three weeks.
- The primary endpoints are safety and tolerability. Secondary endpoints will assess antitumor activity and will inform the recommended single-agent dose and regimen for subsequent studies.
- SGN-CD48A, designed to be high stable in the body, is an antibody-drug conjugate targeting a cell surface protein called CD48 that is highly expressed in MM. The monoclonal antibody that binds to CD48 is linked to a cytotoxic agent called monomethyl auristatin E (MMAE).
- According to ClinicalTrials.gov, the estimated primary completion date is August 2020.